

**Abstract Submission No.: A-1536**

**Comparison of Long Term Outcomes among the Treated and Untreated  
Hepatitis C positive Kidney Transplant Recipients**

**Sana Shadab**<sup>1</sup>, Sanjay Kumar Agarwal<sup>2</sup>, Dipankar Bhowmik<sup>3</sup>, Soumita Bagchi<sup>4</sup>, Shalimar Shalimar<sup>5</sup>, Priyam Batra<sup>6</sup>

<sup>1</sup>Department of Internal Medicine-Nephrology, Assistant Professor, Department Of Nephrology, MLN Medical College, Allahabad, Uttar Pradesh, India, India

<sup>2</sup>Department of Department of Nephrology, A.I.I.M.S, New Delhi, Professor and former Head of the Department, , India

<sup>3</sup>Department of Department of Nephrology, AIIMS, New Delhi, Professor and Head of the Department, India

<sup>4</sup>Department of Department of Nephrology, AIIMS, New Delhi, Additional Professor, India

<sup>5</sup>Department of Department of Gastroenterology, AIIMS, New Delhi, Additional Professor, India

<sup>6</sup>Department of Department of Microbiology, AIIMS, New Delhi, Assistant Professor, India

**Objectives :** To study the long term impact of hepatitis C treatment on the patient and graft outcome in Kidney Transplant Recipients(KTR)

**Methods :** Type of Study - Ambispective cohort study, conducted at A.I.I.M.S,Delhi, from August 2019 to February 2021. Inclusion Criteria - All KTR aged > 18 years, HCV positive before transplant, with at least 1 year follow up post-transplant Exclusion Criteria - coinfectd with Hepatitis B or HIV. Treated group - HCV infected KTR who attained SVR with anti-viral therapy, while Control group included those who could not be treated or non responders to therapy

**Results :** Among 2883 renal transplants done from 1994 to 2019 at our centre, 332 patients were included in the study.114 (34.3%) patients formed the treated group, 86 (75.4%) received DAA, all attained SVR, but only 28 patients (75.6%) treated with IFN had SVR. 218 (65.7%) patients formed the control group. The mean age among the two groups were comparable, 33.0 ± 9.3 years (treated) vs 32.3 ± 9.0 years( untreated). The median follow up was 48 (15-89.5) months in the control group and 40 (25-59) months in the treated group. There was significantly increased mortality among the control group 57 (26.1%) vs the treated group 7 (6.1%), (p <0.001). There were more serious infections seen in the control group; 110 (50.4%) as against the treated group 51 (44.7%), however it was insignificant. HCV treated patients had better graft survival (93%), against 76.2% in control group (p <0.001). The control group had significantly more incidence of liver cirrhosis 19 (8.7%) vs treated group 1 (0.8%) (p=0.004). Out of these 19 patients, 17 (7.7%) developed decompensated liver disease till the last follow up.

**Conclusions :** HCV positive renal transplant recipients who were treated, had significant benefit in terms of patient and graft survival as compared to untreated and non-responsive patients

IMG-20240204-WA0050.jpg

OUTCOME	Total	Treated	Control Group	P
Number of cases	332	114	218	
Duration of follow up in months (Median)*	44 (20-75)	40 (25- 59)	48 (15- 89.5)	<0.005
Post-Transplant Diabetes Mellitus	85 (25.6%)	39 (34.2%)	46 (21.1%)	0.017
Acute rejection	78 (23.4%)	17 (14.9%)	61 (27.9%)	0.009
Patient Mortality	64 (19.2%)	7 (6.1%)	57 (26.1%)	<0.001
Graft loss	60 (18%)	8 (7%)	52 (23.8%)	<0.001
Liver disease	20 (6%)	1 (0.8%)	19 (8.7%)	0.004
Decompensated chronic liver disease	18 (5.4%)	1 (0.8%)	17 (7.7%)	0.008
Liver failure causing death	8 (2.4%)	0	8 (3.6%)	0.055

IMG-20240204-WA0050.jpg

